Table 2. Summary of Grade 3 and Grade 4 Adverse Events in Patients Treated With Vatalanib and Everolimus From Both the Dose-Escalation and Dose-Expansion Cohorts.
| Adverse Event | No. (%) | Grade |
|---|---|---|
| Fatigue | 7 (22.6) | 3 |
| Hypertriglyceridemia | 3 (9.7) | 3 |
| Diarrhea | 3 (9.7) | 3 |
| Anorexia | 2 (6.5) | 3 |
| Hypercholesterolemia | 2 (6.5) | 3/4 |
| Rash | 2 (6.5) | 3 |
| Thrombocytopenia | 2 (6.5) | 3 |
| Arrhythmia | 1 (3.2) | 3 |
| Hypercalcemia | 1 (3.2) | 3 |
| Elevated Alkaline Phosphatase | 1 (3.2) | 3 |
| Mucositis | 1 (3.2) | 3 |
| Nausea | 1 (3.2) | 3 |
| Neutropenia | 1 (3.2) | 3 |
| Pain, Bone | 1 (3.2) | 3 |
| Pain, Feet | 1 (3.2) | 3 |
| Hypertension | 1 (3.2) | 4 |
| Leukoencephalopathy | 1 (3.2) | 4 |
| Asthenia | 1 (3.2) | 3 |
| Infection, Calf | 1 (3.2) | 3 |